^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

SVC112

i
Other names: SVC112
Associations
Trials
Company:
SuviCa
Drug class:
Protein synthesis inhibitor
Associations
Trials
4years
Inhibiting translation elongation with SVC112 suppresses cancer stem cells and inhibits growth in head and neck squamous carcinoma. (PubMed, Cancer Res)
SVC112 had greater antiproliferative effects on HNSCC cells compared with the FDA-approved translation inhibitor omacetaxine mepesuccinate (HHT). SVC112 increased cell cycle progression delay and slowed DNA repair following radiation, enhancing colony and sphere formation radiation effects. In summary, these data demonstrate that SVC112 suppresses CSC-related proteins, enhances the effects of radiation, and blocks growth of HNSCC PDXs by inhibiting CSCs.
Journal
|
SOX2
|
Synribo (omacetaxine mepesuccinate) • SVC112